Introduction
============

Diallyl disulfide (DADS) is a major sulfuric compound of garlic, and exerts anti-inflammatory, immune-modulatory, and enhanced sympathetic activity effects. In the past few years, an increasing number of studies have indicated that DADS has antitumor activity in numerous types of tumors, including in neuroblastoma, breast cancer, colon cancer, lung cancer and stomach cancer ([@b1-ol-0-0-8139]--[@b8-ol-0-0-8139]). The proteomic analysis of 18 differing types of protein in HL-60 cells treated with DADS confirmed that parkinsonism associated deglycase (DJ-1) protein expression was significantly downregulated ([@b9-ol-0-0-8139]). DJ-1 protein, a 20 kDa size protein, belongs to the Thi/PfpI protein superfamily and is expressed in lung, prostate and breast cancer that appears in the serum of patients meaning it may be used as a biomarker for breast cancer and melanoma ([@b10-ol-0-0-8139]). The carcinogenicity of DJ-1 is attributed to a number of factors. Firstly, the cancer may survive the antioxidant effect of the DJ-1 protein; and secondly, DJ-1 has the additional ability to resist apoptosis by the chelation of tumor protein p53, thus reducing the expression of BCL2 associated X apoptosis regulator and preventing caspase activation to inhibit target cell death, or by adjusting phosphatase and tensin homologue (PTEN) activity ([@b11-ol-0-0-8139]). DJ-1 protein is a particularly attractive target for cancer treatment as it is associated with proliferation, invasion, migration, chemotherapeutic resistance and apoptosis ([@b12-ol-0-0-8139]). In the human laryngeal carcinoma cell line snu-46, the enhanced expression of the DJ-1 gene resulted in invasion and migration capability enhancement ([@b13-ol-0-0-8139]), which has also been observed in nasopharyngeal carcinoma ([@b14-ol-0-0-8139]).

The extensive local invasion and early systemic spread, and DJ-1 has been identified to regulate Src phosphorylation in the extracellular signaling pathway to promote cell migration, and invasion ([@b15-ol-0-0-8139]). The Src signaling pathway is associated with tumor invasion and migration, and an experimental study on the transplantation of a pancreatic tumor model indicated that the migration and invasion of pancreatic cancer cells was associated with the Src signaling pathway ([@b16-ol-0-0-8139]). Human non-small cell lung cancer cell line A549 may inhibit Src signaling pathways in order to weaken the cell invasion and migration ([@b17-ol-0-0-8139]). The activation of the Src signaling pathway was revealed to regulate the migration of cells in breast cancer tissue ([@b18-ol-0-0-8139]). In the present study, HL-60 cells with a high expression of DJ-1 in the nucleus (HHDN) were used to analyze the anti-invasion and anti-migration effects resulting from DADS treatment, and its mechanism. Western blot analysis, Transwell migration and invasion chamber assays were used to examine the mechanism of how DADS impacts the invasion, and migration ability in HHDN. Thus, providing novel prospects for the intervention and treatment of leukemia, and a theoretical basis for the optimization of DADS treatment for its antitumor effects.

Materials and methods
=====================

### Cell culture and treatment

HL-60 cells, obtained from the Cancer Research Institute, Xiangya Medical College, Central South University of China, were cultured in RPMI-1640 medium (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) with 10% fetal calf serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) at 37°C in a 5% CO~2~ incubator. Cell culture was replaced with fresh medium every 2--3 days. The Cancer Research Institute of Central South University of China had previous successfully established stable HHDN, as well as an empty vector cell line of HL-60.

### Reagents

DADS (purity 80%, with the remaining 20% composed of diallyl trisulfide and diallyl sulfide), which was purchased from Honeywell Fluka^™^ (Thermo Fisher Scientific, Inc.), was dissolved in Tween-80 at a concentration of 8 mg/ml and stored at −20°C. DJ-1 monoclonal antibodies were purchased from Upstate Biotechnology, Inc., (Lake Placid, NY, USA; cat no. 05-828; 1:2,000 dilution). Fak and Src monoclonal antibodies were purchased from Abgent, Inc. (San Diego, CA, USA; cat no. A01386a; 1:1,000 dilution and cat no. AM7718a; 1:500 dilution, respectively). Phosphorylated Src (p-Src) was purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA; cat. no. 2101; 1:1,000 dilution) and phosphorylated Fak (p-Fak) was purchased from Abgent, Inc. (cat no. AJ1285e; 1:1,000 dilution). β-actin monoclonal antibodies were purchased from Abgent, Inc. (cat. no. AM1021B-ev; 1:2,000 dilution).

### Determination of cell viability

Cells were plated at a density of 1×10^4^ cells/well in 96-well plates, and the cell viability was determined using a conventional MTT reduction assay according to the manufacturer\'s protocol. MTT assays rely primarily on the mitochondrial metabolic capacity of viable cells and reflect the intracellular redox state. Cells were treated with 0.00, 1.25, 2.50, 5.00, 10.00 or 20.00 mg/l of Src inhibitor for 48 h at 37°C. The medium was removed and 100 µl of DMSO was added to each well to dissolve the formed formazan dye crystals for 15 min, subsequently the absorbance at 570 nm was measured using a microplate reader (Molecular Devices, LLC, Sunnyvale, CA, USA). Results were expressed as the percentage of the MTT reduction, assuming that the absorbance of the control was 100%.

### Western blot analysis

Cultures of HL-60 cells in the logarithmic growth phase at a density of 2×10^5^ cells/ml were harvested, washed with ice-cold PBS, and suspended in 0.5 ml lysis buffer (10 mmol/l Tris-HCl pH 7.6, 100 mmol/l NaCl, 1.0 mmol/l ethylenediaminetetraacetic acid and 100 mg/l phenylmethylsulfonyl fluoride) containing protease inhibitor aprotinin (1 mg/l). Lysates were centrifuged at 8,000 × g for 10 min at 37°C, and the protein concentrations in extracts were quantified using a bicinchoninic acid protein quantified kit according to the manufacturer\'s protocol. (Pierce; Thermo Fisher Scientific, Inc.). Total protein (20--25 µg) was separated using 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to a polyvinylidene fluoride membrane. The membrane was blocked using 5% nonfat milk in Tris-buffered saline (TBS) containing 0.1% Tween-20 for 2 h at room temperature and incubated for 2 h at room temperature with a 1:1,000 dilution of DJ-1 monoclonal antibodies. The antibody treated membrane was washed 3 times for 5 min in TBS containing 0.1% Tween-20 and then incubated with a 1:1,000 dilution of horseradish peroxidase (HRP)-conjugated secondary antibody (Sheep anti-rabbit immunoglobulin-HRP; cat no. KGAA35; 1:1,000 dilution; Nanjing KeyGen Biotech Co., Ltd., Nanjing, China) for 1 h at room temperature. The membrane was washed again 3 times for 10 min with TBS containing 0.1% Tween and developed by an enhanced Chemiluminescence Plus kit according to the manufacturer\'s protocol (cat no. CW0049M; Beijing ComWin Biotech Co., Ltd., Beijing, China). Experimental data were analyzed using GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA, USA). Where indicated, the blots were stripped and reprobed with antibodies directed against β-actin (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany).

### Transwell cell migration assay

Logarithmic growth phase cells were collected and centrifuged at 200 × g for 5 min. Subsequently, the supernatant was discarded and serum-free medium (RPMI-1640 medium; Hyclone; GE Healthcare Life Sciences) was added to form the cell suspension, adjusting the cell concentration to 2×10^5^ cells/ml. A total of 500 µl culture medium containing a 0.1 volume fraction of fetal bovine serum was added to 24-well plates, which were placed in the Transwell chamber, and 200 µl cell suspension was added and incubated at 37°C in a volume fraction of 0.05 CO~2~ for 24 h. Seeded in 96-well plates, each well had 20 µl MTT solution added and incubation continued for 4 h. Centrifugation was performed at 400 × g for 5 min at 37°C, and DMSO (150 µl) was added to each well, agitated for 20 min in a flat shaker, Subsequently, the absorbance of each well was measured using ELISA at a 450 nm wavelength (cat no. ab100578; Abcam, Cambridge, UK) according to the manufacturer\'s protocol.

### Transwell cell invasion assay

Solid Matrigel was placed in the refrigerator overnight at 4°C and then dissolved into liquid. A 24-well culture plate was placed into the Transwell chamber, and diluted Matrigel (50 µl) was added to each chamber under 15°C. Subsequently, it was placed into a cell incubator overnight Logarithmic growth phase cells were collected, the serum removed and RPMI-1640 medium (Hyclone; GE Healthcare, Chicago, IL, USA) prepared as the cell suspension, which adjusted the cell concentration to 2×10^5^ cells/ml. In the 24-well plates placed in the lower chamber, a 0.1 volume fraction of fetal bovine serum medium (500 µl) was added, in addition to 200 µl cell suspension and cultured for 24 h. The chamber was immersed in 4% paraformaldehyde for 30 min at 37°C and rinsed two times with PBS. Then, when completely dry, staining was performed using a pre-diluted 1:9 Giemsa dye liquor at room temperature for 20--30 min. Subsequently it was rinsed with deionized water several times, and several sections were selected at random to be visualized under the light microscope (magnification, ×20). The number of cells were then calculated.

### Statistical analysis

Data are expressed as the mean ± the standard deviation. The significance of inter-group differences was evaluated using a one-way analysis of variance with Scheffe\'s test used for post hoc comparisons. Transwell and western blot data were analyzed using SPSS statistical software (version 18.0; SPSS, Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### DADS treatment affects the expression levels of DJ-1 protein in HL-60 cells

In order to test the effect of DADS on the expression levels of DJ-1 protein in HL-60 cells, the DJ-1 protein expression levels were measured following DADS treatment in HL-60. Western blot analysis results indicated that the expression levels of DJ-1 protein in HHDN cells treated with DADS for 24, 48 and 72 h was significantly reduced, demonstrating a time-dependent decrease (P\<0.05; [Fig. 1](#f1-ol-0-0-8139){ref-type="fig"}).

### DADS affects the Src signaling pathway in HHDN cells

In order to test the effect of DADS treatment on the Src signaling pathway, the protein expression levels of DADS-treated HHDN cells at time intervals of 0, 5, 15, 30 and 60 min was examined. Compared with untreated cells, after HL-60 cells were treated with DADS for 30 min, the expression of p-Src and p-Fak was gradually inhibited ([Fig. 2A](#f2-ol-0-0-8139){ref-type="fig"}). It also demonstrated a direct decline in protein expression levels with an increase in DADS treatment time ([Fig. 2B](#f2-ol-0-0-8139){ref-type="fig"}). The protein expression levels of Src and Fak almost reached zero after 60 min of treatment, when the expression of Src and Fak was absolutely inhibited.

After 30 min of treatment with DADS, in a control group, empty vector group and high expression group, the expression levels of p-Frk and p-Src compared with the untreated groups was significantly reduced, with a statistically significant difference (P\<0.05; [Fig. 3](#f3-ol-0-0-8139){ref-type="fig"}). No significant difference was identified in the high expression group compared with the control group and empty vector group (P\>0.05), indicating that DADS may inhibit the Src signaling pathway. Additionally, in the three groups of cells without DADS treatment, Src and Fak were highly expressed compared with treated cells. In leukemia cells, the Src signaling pathway is in an activated state.

### Effect of DADS and Src inhibitor on the Src signaling pathway of HHDN cells

Following treatment with DADS and Src inhibitor, the expression levels of p-Src and p-Fak compared with the untreated group were significantly inhibited, and the difference was statistically significant (P\<0.05; [Fig. 4](#f4-ol-0-0-8139){ref-type="fig"}). However, there was no significant difference between the high expression group and the control group and empty vector group (P\>0.05). The results demonstrated that DADS and Src inhibitors may be combined to inhibit the Src signaling pathway.

### Effect of DADS and Src inhibitor on the DJ-1 protein expression levels of HHDN cells

Compared with the untreated group, DJ-1 protein expression levels demonstrated a time-dependent decrease with DADS and Src inhibitor treated HHDN at 24, 48 and 72 h, with a statistically significant difference (P\<0.05), indicating that the DJ-1 gene may be a potential therapeutic target ([Fig. 5](#f5-ol-0-0-8139){ref-type="fig"}).

### Effect of DADS and Src inhibitor treatment on the invasion and migration ability of HHDN cells

It was revealed that in the high expression cells of each group compared with the control group, the high expression group presented a significantly higher migration rate (P\<0.05), which demonstrated a positive association between the high expression of DJ-1 and the migration of HL-60 cells ([Table I](#tI-ol-0-0-8139){ref-type="table"}, [Fig. 6](#f6-ol-0-0-8139){ref-type="fig"}). Following treatment with DADS for 24 h, the cell migration rate of the two groups decreased significantly compared with the control (P\<0.05), while the groups treated with Src inhibitor for 24 h presented no significant difference compared with the DADS groups (P\>0.05). Groups treated with combined DADS and Src inhibitor treatment presented a significantly lower cell migration rate compared with groups treated with either DADS or Src inhibitor alone (P\<0.05). All results indicate that DADS and Src inhibitor treatments individually inhibit leukemia cell migration, and demonstrate synergistic effects on the inhibition of leukemia cell migration.

The invasion cell numbers through the matrigel in the high expression groups were greater compared with the numbers in the control groups, which indicated a positive association between the high expression of DJ-1 and the invasion ability of HL-60 cells. Following treatment with DADS for 24 h, the number of cells counted that had invaded through the matrigel in the DADS treated group had decreased significantly compared to the untreated group, however no difference was apparent compared with the groups treated with Src inhibitor treatment for 24 h (P\>0.05). Furthermore, the groups treated with combined DADS and Src inhibitor demonstrated a lower cell count compared with the groups treated with either DADS or Src inhibitor alone (P\<0.05; [Table II](#tII-ol-0-0-8139){ref-type="table"} and [Fig. 7](#f7-ol-0-0-8139){ref-type="fig"}). The results revealed that DADS and Src inhibitor treatments individually inhibit leukemia cell invasion, and demonstrated synergistic effects on the inhibition of leukemia cell invasion.

Discussion
==========

DADS, an organic sulfuric compound present in garlic, is a promising anticancer candidate that inhibits a variety of types of tumor ([@b19-ol-0-0-8139]--[@b23-ol-0-0-8139]). In tumor cell differentiation, cell cycle regulation and apoptosis, it may inhibit the expression of certain oncogenes ([@b24-ol-0-0-8139]). In addition, one study has demonstrated that DADS exhibits stronger antitumor effects compared with cisplatin on certain tumors, and presents fewer side effects ([@b25-ol-0-0-8139]).

In clinical practice, \>90% of patients with cancer succumb due to tumor invasion and metastasis ([@b26-ol-0-0-8139]). A previous study has demonstrated that DADS significantly inhibited the proliferation of HL-60 cells cultured *in vitro* in a dose-responsive manner. Moderate doses (\>1.25 mg/l) may induce apoptosis in HL-60 cells, whereas low-dose DADS (\<1.25 mg/l) induced the differentiation of HL-60 cells ([@b27-ol-0-0-8139]). It was preliminarily identified that DADS is able to induce the expression of 18 differing types of protein in human leukemia HL-60 cells, of which DJ-1 protein may be downregulated, which belongs to a cancer-causing protein family associated with oncogenesis and development ([@b28-ol-0-0-8139]).

DJ-1 is an oncogenic protein that regulates the interaction between proteins and RNA, and previous studies have revealed that DJ-1 is highly expressed in lung, esophageal, pancreatic, liver, breast and laryngeal cancer, as well as other malignant tumors ([@b29-ol-0-0-8139]--[@b32-ol-0-0-8139]). Upregulated expression of the DJ-1 gene may promote oncogenesis, and inhibit the reduce proliferation of chemotherapeutic drugs against cancer cells, which is associated with chemotherapeutic resistance. These studies suggest that the cancer-promoting gene DJ-1 may be used to diagnose and predict prognosis in patients with cancer, and has potential value in clinical practice ([@b33-ol-0-0-8139]).

DJ-1, expressed in the cytoplasm, nucleus and mitochondria, is a regulatory molecule of gene transcription. In the S phase, it is transferred from the cytoplasm to the nucleus, and DJ-1 expressed in different subcellular locations regulates different physiological and pathological features. If expression is localized to the mitochondria, then it is involved in oxidative stress process ([@b33-ol-0-0-8139],[@b34-ol-0-0-8139]), whilst nuclear localized expression inhibits apoptosis ([@b35-ol-0-0-8139],[@b36-ol-0-0-8139]). DJ-1 highly expressed in the nucleus promotes HL-60 cell proliferation and migration, and enhances invasion capability, but an interfering DJ-1 gene is able to enhance proliferation inhibition against DADS and induce the differentiation of HL-60 cells ([@b37-ol-0-0-8139]).

HHDN are a highly invasive cell line, as the migration and invasion ability of tumor cells appears to be associated with highly-expressed DJ-1; however, its mechanism remains unclear ([@b14-ol-0-0-8139],[@b30-ol-0-0-8139],[@b38-ol-0-0-8139]--[@b40-ol-0-0-8139]). In the present study, western blot analysis was used to examine how DADS affects the expression of the DJ-1 protein in HHND cells, and the DJ-1 protein expression levels revealed a time-dependent decrease with DADS-treatment. Thus, it was posited that DADS may downregulate the expression of DJ-1, and inhibit the migration and invasion ability of HHND cells. However, the specific mechanism remains unknown and is yet to be confirmed.

DJ-1 promotes tumor cell division, proliferation, migration and invasion, and is likely to be involved in several coordinated intracellular molecular pathways. Li *et al* ([@b41-ol-0-0-8139]) reported that the DJ-1 protein is one of the major negative regulator proteins of the PTEN tumor suppressor gene. DJ-1 protein promotes tumor cell proliferation and growth by inhibiting PTEN activity, and stimulating the phosphoinositide 3-kinase/protein kinase B signaling pathway ([@b42-ol-0-0-8139]). DJ-1 promotes nuclear translocation of nuclear factor-κβ, regulates cell differentiation and inhibits apoptosis ([@b43-ol-0-0-8139]). DJ-1 regulates the transcription factor nuclear factor erythroid 2-related factor 2 signaling pathway and promotes cytoprotective gene expression ([@b44-ol-0-0-8139]). It is also a target of regulation of Src and extracellular signal-regulated kinase signaling pathways, promoting tumor cell proliferation, migration and invasion ([@b45-ol-0-0-8139]).

It was revealed that integrins are associated with tumor cell adhesion, migration and invasion in a transplanted tumor model of breast cancer in zebrafish, and mice ([@b46-ol-0-0-8139],[@b47-ol-0-0-8139]). The extracellular matrix-integrin signal transduction pathway is involved with the Src signaling pathway, where Fak is a key factor. Under the action of integrin, Fak phosphorylates and interacts with Src ([@b48-ol-0-0-8139]). An experimental study has confirmed that interfering PTEN may inhibit the phosphorylation of Fak so as to inhibit the proliferation, migration and invasion of liver cancer, and leukemia cell ([@b42-ol-0-0-8139]). Thus, it was hypothesized that DJ-1 and Src signaling pathways may be potentially associated in the invasion, and migration of leukemic cells ([@b49-ol-0-0-8139]). Scr promotes cell proliferation, adhesion, migration and invasion in tumorigenesis ([@b50-ol-0-0-8139]). Src activation is required for induction of integrin ([@b51-ol-0-0-8139]). In the present study, a western blot analysis was used to examine how DADS influences the Src signaling pathways in HHND cells, and further confirmed that DADS may inhibit the invasion of and migration of HHND cells through negative regulation of the Src signaling pathway. The results revealed that DADS may inhibit the Src signaling pathway.

Src kinases in targeted therapy is an important topic ([@b52-ol-0-0-8139]). Inhibiting Src activity may inhibit the proliferation of a variety of types of tumor, including the invasive migratory effect ([@b53-ol-0-0-8139],[@b54-ol-0-0-8139]). In the present study, it was revealed that Src treatment may inhibit the migration and invasion ability of leukemia cells, whereas the combination of DADS and Src treatments demonstrated more significant inhibitory effects. Therefore, it may be considered that antagonizing the Src signaling pathway inhibits the invasion and migration ability of leukemia cells.

In conclusion, DADS suppresses the invasion and migration of HHND cells by antagonizing the Src signaling pathway and downregulating its expression. It was demonstrated that DJ-1 may be a potential target for gene therapy, and may improve the DADS antitumor effect on leukemia. Finally, Src inhibitor combined with DADS treatment may be used as a type of therapy to achieve more improved antitumor effects, providing a more safe and effective drug for patients with leukemia.
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![Analysis of the expression levels of DJ-1 protein in HL-60 cells treated with DADS for 0, 24, 48 and 72 h. (A) A representative western blot analysis presenting DJ-1 expression in HL-60 cells treated with DADS for differing lengths of time. (B) Quantification of the DJ-1 expression levels in western blot analyses. \*P\<0.05 vs. the control. DJ-1, parkinsonism associated deglycase; DADS, diallyl disulfide.](ol-15-05-6377-g00){#f1-ol-0-0-8139}

![The expression of p-Src and p-Fak in the HL-60 cells with a high expression of DJ-1 in the nucleus induced by diallyl disulfide for 0, 5, 15, 30 or 60 min. (A) A representative western blot analysis presenting the expression of p-Src and p-Fak. (B) Comparisons between the expression levels of p-Src and p-Fak. \*P\<0.05 vs. the control. p-Src, phosphorylated Src protein; p-Fak, phosphorylated Fak protein; DJ-1, parkinsonism associated deglycase.](ol-15-05-6377-g01){#f2-ol-0-0-8139}

![DADS affects the Src signaling pathway in a control group, empty vector group and high expression group. (A) Protein expression of p-Src, Src, P-Fak, Fak and integrin was examined using western blot analysis. (B) Quantified protein expression of p-Src and p-Fac across the three groups. \*P\<0.05 vs. the control. DADS, diallyl disulfide; DJ-1, parkinsonism associated deglycase; p-Src, phosphorylated Src protein; p-Fak, phosphorylated Fak protein.](ol-15-05-6377-g02){#f3-ol-0-0-8139}

![DADS and Src inhibitor inhibit the Src signaling pathway in the control group, the empty vector group and the high expression group. Protein expression of p-Src, Src, P-Fak, Fak and integrin was examined by (A) western blot analysis and (B) quantitative analysis. \*P\<0.05 vs. the control. DADS, diallyl disulfide; p-Src, phosphorylated Src protein; p-Fak, phosphorylated Fak protein; DJ-1, parkinsonism associated deglycase.](ol-15-05-6377-g03){#f4-ol-0-0-8139}

![Western blot analysis of the effect of diallyl disulfide and Src inhibitor on the DJ-1 protein expression levels in HL-60 cells with a high expression of DJ-1 in the nucleus at 0, 24, 48 and 72 h. (A) A representative western blot analysis for DJ-1. (B) Quantification of DJ-1 expression levels in western blot analyses. \*P\<0.05 vs. the control. DJ-1, parkinsonism associated deglycase.](ol-15-05-6377-g04){#f5-ol-0-0-8139}

![Effect of DADS and Src inhibitor treatments on the migration ability of HL-60 cells with a high expression of DJ-1 in the nucleus. \*P\<0.05 vs. the control group; ^\#^P\<0.05 vs. untreated; ^∆^P\<0.05 vs. the DADS group and Src inhibitor group. DADS, diallyl disulfide; DJ-1, parkinsonism associated deglycase; OD, optical density.](ol-15-05-6377-g05){#f6-ol-0-0-8139}

![Effect of DADS and Src inhibitor on the invasion of HHDN (magnification, ×20). (A) The invasion ability of untreated ([@b1-ol-0-0-8139]) HHDN and ([@b2-ol-0-0-8139]) HL-60 cells. (B) The invasion ability of DADS-treated ([@b1-ol-0-0-8139]) HHDN and ([@b2-ol-0-0-8139]) HL-60 cells. (C) The invasion ability of Src inhibitor-treated ([@b1-ol-0-0-8139]) HHDN and ([@b2-ol-0-0-8139]) HL-60 cells. (D) The invasion ability of combined DADS and Src inhibitor-treated ([@b1-ol-0-0-8139]) HHDN and ([@b2-ol-0-0-8139]) HL-60 cells. P\<0.05 vs. untreated. DADS, diallyl disulfide; HHDN, HL-60 cells with a high expression of DJ-1 in the nucleus; DJ-1, parkinsonism associated deglycase.](ol-15-05-6377-g06){#f7-ol-0-0-8139}

###### 

Effect of DADS and Src inhibitor treatments on the migration ability of HHDN cells.

  Group   No treatment group                                        DADS-treated group                                                                                    Src inhibitor-treated group                                                                           Combined treatment group
  ------- --------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  HHDN    1.514±0.04^[a](#tfn1-ol-0-0-8139){ref-type="table-fn"}^   1.117±0.03^[b](#tfn2-ol-0-0-8139){ref-type="table-fn"},[a](#tfn1-ol-0-0-8139){ref-type="table-fn"}^   1.163±0.02^[b](#tfn2-ol-0-0-8139){ref-type="table-fn"},[a](#tfn1-ol-0-0-8139){ref-type="table-fn"}^   0.929±0.04^[c](#tfn3-ol-0-0-8139){ref-type="table-fn"},[a](#tfn1-ol-0-0-8139){ref-type="table-fn"}^
  HL-60   1.136±0.05                                                0.739±0.04^[b](#tfn2-ol-0-0-8139){ref-type="table-fn"}^                                               0.775±0.02^[b](#tfn2-ol-0-0-8139){ref-type="table-fn"}^                                               0.516±0.03^[c](#tfn3-ol-0-0-8139){ref-type="table-fn"}^

P\<0.05 vs. the control group

P\<0.05 vs. the untreated group

P\<0.05 vs. the DADS group and Src inhibitor group. DADS, diallyl disulfide; HHND, HL-60 cells with a high expression of DJ-1 in the nucleus; DJ-1, parkinsonism associated deglycase.

###### 

Effect of DADS and Src inhibitor treatments on the invasion ability of HHDN.

  Group         No treatment group                                         DADS-treated group                                                                                     Src inhibitor-treated group                                                                            Combined treatment group
  ------------- ---------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------
  HHDN          221.7±5.897^[a](#tfn4-ol-0-0-8139){ref-type="table-fn"}^   155.3±6.173^[a](#tfn4-ol-0-0-8139){ref-type="table-fn"},[b](#tfn5-ol-0-0-8139){ref-type="table-fn"}^   162.7±3.844^[a](#tfn4-ol-0-0-8139){ref-type="table-fn"},[b](#tfn5-ol-0-0-8139){ref-type="table-fn"}^   89.67±4.910^[a](#tfn4-ol-0-0-8139){ref-type="table-fn"},[c](#tfn6-ol-0-0-8139){ref-type="table-fn"}^
  HL-60 cells   175.3±6.642                                                117.3±5.783^[b](#tfn5-ol-0-0-8139){ref-type="table-fn"}^                                               122.3±3.930^[b](#tfn5-ol-0-0-8139){ref-type="table-fn"}^                                               73.67±4.410^[c](#tfn6-ol-0-0-8139){ref-type="table-fn"}^

P\<0.05 vs. the control group

P\<0.05 vs. the untreated group

P\<0.05 vs. the DADS group and Src inhibitor group. DADS, diallyl disulfide; HHDN, HL-60 cells with a high expression of DJ-1 in the nucleus; DJ-1, parkinsonism associated deglycase.

[^1]: Contributed equally
